Johnson & JohnsonNYSE:JNJ
- LAST PRICE145.3100
- TODAY'S CHANGE (%)0.8700 (0.6023%)
- Bid / Lots145.3000/ 2
- Ask / Lots145.3300/ 2
- Open / Previous Close144.6200 / 144.4400
- Day Range
- 52 Week Range
- Volume3,460,545
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | JNJ |
|---|---|---|
| 09:32 ET | 127316 | 144.59 |
| 09:34 ET | 24934 | 144.52 |
| 09:36 ET | 27222 | 144.56 |
| 09:38 ET | 22023 | 144.57 |
| 09:39 ET | 22158 | 144.2084 |
| 09:41 ET | 12614 | 144.33 |
| 09:43 ET | 12562 | 144.29 |
| 09:45 ET | 11238 | 144.1836 |
| 09:48 ET | 9449 | 144.16 |
| 09:50 ET | 17766 | 144.0899 |
| 09:52 ET | 16545 | 144.16 |
| 09:54 ET | 15766 | 144.23 |
| 09:56 ET | 12765 | 144.22 |
| 09:57 ET | 10446 | 144.05 |
| 09:59 ET | 17846 | 144.31 |
| 10:01 ET | 20295 | 144.35 |
| 10:03 ET | 19122 | 144.69 |
| 10:06 ET | 18971 | 144.54 |
| 10:08 ET | 13536 | 144.5 |
| 10:10 ET | 20226 | 144.52 |
| 10:12 ET | 33408 | 144.68 |
| 10:14 ET | 14011 | 144.7 |
| 10:15 ET | 35081 | 144.44 |
| 10:17 ET | 11085 | 144.4896 |
| 10:19 ET | 8794 | 144.385 |
| 10:21 ET | 9191 | 144.347 |
| 10:24 ET | 12441 | 144.415 |
| 10:26 ET | 11973 | 144.39 |
| 10:28 ET | 6974 | 144.33 |
| 10:30 ET | 16115 | 144.32 |
| 10:32 ET | 22742 | 144.39 |
| 10:33 ET | 44936 | 144.64 |
| 10:35 ET | 57383 | 145.08 |
| 10:37 ET | 51653 | 145.02 |
| 10:39 ET | 47527 | 145.12 |
| 10:42 ET | 21484 | 145.105 |
| 10:44 ET | 18577 | 145.09 |
| 10:46 ET | 18458 | 145.085 |
| 10:48 ET | 12358 | 144.96 |
| 10:50 ET | 12411 | 144.81 |
| 10:51 ET | 13129 | 144.775 |
| 10:53 ET | 7721 | 144.9 |
| 10:55 ET | 8408 | 144.73 |
| 10:57 ET | 13520 | 144.715 |
| 11:00 ET | 9745 | 144.755 |
| 11:02 ET | 11506 | 144.88 |
| 11:04 ET | 8556 | 144.91 |
| 11:06 ET | 7529 | 144.81 |
| 11:08 ET | 3968 | 144.8 |
| 11:09 ET | 6241 | 144.85 |
| 11:11 ET | 19317 | 144.855 |
| 11:13 ET | 12770 | 144.91 |
| 11:15 ET | 11356 | 144.76 |
| 11:18 ET | 22178 | 144.89 |
| 11:20 ET | 24404 | 144.9943 |
| 11:22 ET | 22566 | 144.917 |
| 11:24 ET | 7894 | 144.89 |
| 11:26 ET | 25276 | 144.93 |
| 11:27 ET | 12400 | 144.9449 |
| 11:29 ET | 5535 | 144.943 |
| 11:31 ET | 20526 | 145 |
| 11:33 ET | 9827 | 145.035 |
| 11:36 ET | 5039 | 145.0001 |
| 11:38 ET | 17708 | 145.03 |
| 11:40 ET | 20341 | 145.0337 |
| 11:42 ET | 12212 | 145.08 |
| 11:44 ET | 13702 | 145.1095 |
| 11:45 ET | 25974 | 145.215 |
| 11:47 ET | 27893 | 145.2499 |
| 11:49 ET | 11736 | 145.24 |
| 11:51 ET | 43978 | 145.26 |
| 11:54 ET | 8103 | 145.2548 |
| 11:56 ET | 15860 | 145.245 |
| 11:58 ET | 7840 | 145.17 |
| 12:00 ET | 5988 | 145.1675 |
| 12:02 ET | 13055 | 145.181 |
| 12:03 ET | 8721 | 145.225 |
| 12:05 ET | 8260 | 145.265 |
| 12:07 ET | 13114 | 145.32 |
| 12:09 ET | 13085 | 145.3195 |
| 12:12 ET | 5513 | 145.21 |
| 12:14 ET | 8342 | 145.3 |
| 12:16 ET | 7129 | 145.35 |
| 12:18 ET | 4394 | 145.25 |
| 12:20 ET | 5532 | 145.295 |
| 12:21 ET | 8320 | 145.28 |
| 12:23 ET | 17420 | 145.31 |
| 12:25 ET | 21445 | 145.3288 |
| 12:27 ET | 4317 | 145.32 |
| 12:30 ET | 11716 | 145.19 |
| 12:32 ET | 26728 | 145.2 |
| 12:34 ET | 13444 | 145.17 |
| 12:36 ET | 9809 | 145.2 |
| 12:38 ET | 5148 | 145.2616 |
| 12:39 ET | 10716 | 145.22 |
| 12:41 ET | 11644 | 145.23 |
| 12:43 ET | 12256 | 145.205 |
| 12:45 ET | 10700 | 145.3042 |
| 12:48 ET | 12226 | 145.35 |
| 12:50 ET | 3219 | 145.32 |
| 12:52 ET | 8965 | 145.3169 |
| 12:54 ET | 6132 | 145.31 |
Yesterday
Sarepta Therapeutics Set to Join S&P MidCap 400, from 19 hours ago by Dow Jones
19 hours ago by Dow Jones
May 28, 2024
DJ J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Bln Deal, from 7:54AM ET on Tuesday May 28, 2024 by Dow Jones
7:54AM ET on Tuesday May 28, 2024 by Dow JonesNumab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis, from 7:35AM ET on Tuesday May 28, 2024 by Dow Jones
7:35AM ET on Tuesday May 28, 2024 by Dow JonesJohnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis, from 7:30AM ET on Tuesday May 28, 2024 by Dow Jones
7:30AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Johnson & Johnson | 347.6B | 21.3x | -1.47% |
Merck & Co Inc | 318.9B | 143.1x | -43.23% |
Roche Holding AG | 206.2B | 16.2x | +3.28% |
AbbVie Inc | 273.3B | 46.4x | -6.05% |
AstraZeneca PLC | 236.0B | 37.9x | +17.52% |
Pfizer Inc | 157.6B | -460.8x | -7.10% |
Company Information
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
Contact Information
- Headquarters
- One Johnson & Johnson PlazaNEW BRUNSWICK, NJ, United States 08933
- Phone
- 732-524-2455
- Fax
- 732-214-0332
Executives
- Chairman of the Board, Chief Executive Officer
- Joaquin Duato
- Chief Financial Officer, Executive Vice President
- Joseph Wolk
- Chief Human Resource Officer, Executive Vice President
- Peter Fasolo
- Executive Vice President, Chief Technology Officer and Risk Officer
- Kathryn Wengel
- Executive Vice President, Chief Information Officer
- James Swanson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $347.6B |
|---|---|
Revenue (TTM) | $85.6B |
Shares Outstanding | 2.4B |
Dividend Yield | 3.41% |
Annual Dividend Rate | 4.9600 USD |
Ex-Dividend Date | 05-20-24 |
Pay Date | 06-04-24 |
Beta | 0.53 |
EPS | $6.81 |
Book Value | $28.57 |
P/E Ratio | 21.3x |
Price/Sales (TTM) | 4.1 |
Price/Cash Flow (TTM) | 14.4x |
Operating Margin | 23.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
